GlobeNewswire·Nov 10, 2026, 4:01 PM ET

Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results

EPRX

Eupraxia Pharmaceuticals reached the target enrollment of 120 patients for the Phase 2b placebo-controlled blinded portion of the RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE) as of October 15, 2026.
Interim analysis results from the Phase 2b portion of the RESOLVE trial are expected in December 2026.
Cash reserves of $75.2 million in cash equivalents and $51.2 million in short-term investments as of September 30, 2026, provide a runway into the second half of 2028.
The company reported a net loss of $15.2 million for the third quarter ended September 30, 2026, compared to $6.4 million in the same period the previous year, driven by increased research and development costs.
Open-label Phase 1b/2a data showed a reduction in moderate to severe odynophagia from 62% at baseline to 25% from 24 to 52 weeks post-treatment in cohorts 7-9.
52-week data from the highest dose cohort (Cohort 9) demonstrated that 66% of patients (2 of 3) maintained clinical remission.
Overall, 64% of patients in the open-label trial remained in clinical remission over the 52-week period with clinically meaningful histologic improvements.
Eupraxia transferred its listing to the Nasdaq Global Select Market on September 8, 2026.
The company presented data from the ongoing RESOLVE trial at the American College of Gastroenterology Annual Scientific Meeting in Nashville and the United European Gastroenterology Week in Barcelona during October 2026.
The Phase 2b trial is evaluating 120mg and 160mg doses of EP-104GI administered via esophageal wall injections.
As of September 30, 2026, the company had 67,241,876 common shares, 8,295,638 preferred shares, and 1,428,571 pre-funded warrants outstanding.

Company: Eupraxia Pharmaceuticals Inc.
Keywords: Toronto Stock Exchange:EPRX, Eupraxia Pharmaceuticals Inc.